Showing results (461-470 of 753) with videos related to

Sort By:
Pageof 76
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium studyKurt A Jaeckle, Kenneth R Hess, W K Alfred Yung, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Neuro-Oncology|January 25, 2023
Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volumeElisa Aquilanti, Lauren Kageler, Jacqueline Watson, et al.
Neuro-Oncology|December 10, 2023
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effortJoshua A Budhu, Ugonma N Chukwueke, Sadhana Jackson, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
The Lancet. Oncology|March 7, 2018
Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiativeLinda Dirven, Terri S Armstrong, Jaishri O Blakeley, et al.
Neuro-Oncology|April 12, 2020
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 PandemicNimish A Mohile, Jaishri O Blakeley, Na Tosha N Gatson, et al.
Neuro-Oncology|May 6, 2020
Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV GliomasDenise Bernhardt, Wolfgang Wick, Stephanie E Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Neuro-Oncology|June 25, 2014
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumabRifaquat Rahman, Kelly Hempfling, Andrew D Norden, et al.
Pageof 76